Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uproleselan with Chemotherapy in AML
NCT02306291Phase 2Completed
- Sponsor
- GlycoMimetics
- Start
- Mar 2015
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of uproleselan in acute myeloid leukemia (AML), sponsored by GlycoMimetics. Started Mar 2015; status: completed.
02
Drugs
uproleselan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02306291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02306291.